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Foreword
As the largest organ of the body, the skin performs multiple critical functions, such as 
serving as the primary barrier to the external environment. For this reason, the skin is 
often exposed to potentially hazardous agents, including chemicals, which may contribute 
to the onset of a spectrum of adverse health effects ranging from localized damage (e.g., 
irritant contact dermatitis and corrosion) to induction of immune-mediated responses 
(e.g., allergic contact dermatitis and pulmonary responses), or systemic toxicity (e.g., 
neurotoxicity and hepatoxicity). Understanding the hazards related to skin contact with 
chemicals is a critical component of modern occupational safety and health programs.
In 2009, the National Institute for Occupational Safety and Health (NIOSH) pub-
lished Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin 
Notations [NIOSH 2009–147]. This document provides the scientific rationale and 
framework for the assignment of multiple hazard-specific skin notations (SK) that 
clearly distinguish between the systemic effects, direct (localized) effects, and immune- 
mediated responses caused by skin contact with chemicals. The key step within assign-
ment of the hazard-specific SK is the determination of a substance’s hazard potential, or 
its potential for causing adverse health effects as a result of skin exposure. This determi-
nation entails a health hazard identification process that involves use of the following:
 • Scientific data on the physicochemical properties of a chemical
 • Data on human exposures and health effects
 • Empirical data from in vivo and in vitro laboratory testing
 • Computational techniques, including predictive algorithms and mathematical 
models that describe a selected process (e.g., skin permeation) by means of ana-
lytical or numerical methods. 
This Skin Notation Profile provides the SK assignment and supportive data for methyl 
cellosolve (CAS No. 109–86–4). In particular, this document evaluates and summarizes 
the literature describing the substance’s hazard potential and its assessment according to 
the scientific rationale and framework outlined in CIB 61. In meeting this objective, this 
Skin Notation Profile intends to inform the audience—mostly occupational health prac-
titioners, researchers, policy- and decision-makers, employers, and workers in potentially 
hazardous workplaces—so that improved risk-management practices may be developed 
to better protect workers from the risks of skin contact with the chemical of interest.
John Howard, M.D. 
Director, National Institute for  
   Occupational Safety and Health 
Centers for Disease Control and Prevention
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Abbreviations
ACGIH American Conference of Governmental Industrial Hygienists 
CIB Current Intelligence Bulletin
cm2 square centimeter(s)
cm/hr centimeter(s) per hour
CNS central nervous system
DEREK™ Deductive Estimation of Risk from Existing Knowledge
DIR skin notation indicating the potential for direct effects to the skin 
   following contact with a chemical
EC European Commission 
EEC European Economic Communities
GHS Globally Harmonized System of Classification and Labeling of Chemicals
GPMT guinea pig maximization test
IARC International Agency for Research on Cancer
Kaq  coefficient in the watery epidermal layer 
Kp skin permeation coefficient 
Kpol  coefficient in the protein fraction of the stratum corneum
Kpsc  permeation coefficient in the lipid fraction of the stratum corneum 
LD50  dose resulting in 50% mortality in the exposed population
LDLo dermal lethal dose
LOAEL lowest-observed-adverse-effect level 
log KOW base-10 logarithm of a substance’s octanol–water partition
m3 cubic meter(s)
MCV mean corpuscular volume
mg milligram(s)
mg/cm2/hr milligram(s) per square centimeter per hour
mg/kg milligram(s) per kilogram body weight
mg/kg/day milligram(s) per kilogram body weight per day
mg/m3 milligram(s) per cubic meter
mL milliliter(s)
mL/kg milliliter(s) per kilogram body weight
MW molecular weight
NIOSH National Institute for Occupational Safety and Health
NOAEL no-observed-adverse-effect level
NTP National Toxicology Program
OEL occupational exposure limit
OSHA Occupational Safety and Health Administration
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RBC red blood cell
REL recommended exposure limit
RF retention factor 
SEN skin notation indicating the potential for immune-mediated reactions 
   following exposure of the skin
SI ratio ratio of skin dose to inhalation dose
SK skin notation
SW  solubility 
SYS skin notation indicating the potential for systemic toxicity following 
   exposure of the skin
USEPA United States Environmental Protection Agency 
µL/cm2 microliter(s) per square centimeter
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Glossary 
Absorption—The transport of a chemical from the outer surface of the skin into both 
the skin and systemic circulation (including penetration, permeation, and resorption). 
Acute exposure—Contact with a chemical that occurs once or for only a short period 
of time. 
Cancer—Any one of a group of diseases that occurs when cells in the body become 
abnormal and grow or multiply out of control. 
Contaminant—A chemical that is (1) unintentionally present within a neat substance 
or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen 
and present within a neat substance or mixture at a concentration less than 0.1%. 
Cutaneous (or percutaneous)—Referring to the skin (or through the skin). 
Dermal—Referring to the skin. 
Dermal contact—Contact with (touching) the skin. 
Direct effects—Localized, non-immune-mediated adverse health effects on the skin, 
including corrosion, primary irritation, changes in skin pigmentation, and reduction/
disruption of the skin barrier integrity, occurring at or near the point of contact with 
chemicals. 
Immune-mediated responses—Responses mediated by the immune system, including 
allergic responses. 
Sensitization—A specific immune-mediated response that develops following expo-
sure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis 
(ACD) or other immune-mediated diseases such as asthma, depending on the site and 
route of re-exposure. 
Substance—A chemical. 
Systemic effects—Systemic toxicity associated with skin absorption of chemicals after 
exposure of the skin.
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1.2 Purpose
This Skin Notation Profile presents (1) a 
brief summary of technical data associat-
ed with skin contact with ME and (2) the 
rationale behind the hazard-specific skin 
notation (SK) assignment for ME. The 
SK assignment is based on the scientific 
rationale and logic outlined in the Current 
Intelligence Bulletin (CIB) 61: A Strategy 
for Assigning New NIOSH Skin Notations 
[NIOSH 2009]. The summarized infor-
mation and health hazard assessment are 
limited to an evaluation of the potential 
health effects of dermal exposure to ME. 
A literature search was conducted through 
July 2010 to identify information on ME, 
including but not limited to data relating 
to its toxicokinetics, acute toxicity, repeated- 
dose systemic toxicity, carcinogenicity, bi-
ological system / function–specific effects 
(including reproductive and developmen-
tal effects and immunotoxicity), irritation, 
and sensitization. Information was con-
sidered from studies of humans, animals, 
or appropriate modeling systems that are 
relevant to assessing the effects of dermal 
exposure to ME. 
1.3 Overview of SK Assignment for 
Methyl Cellosolve
Methyl cellosolve is potentially capable 
of causing multiple adverse health effects 
following skin contact. A critical review of 
available data has resulted in the following 
SK assignment for methyl cellosolve: SK: 
SYS. Table 1 provides an overview of the 
critical effects and data used to develop 
the SK assignment for methyl cellosolve. 
The following section provides additional 
details about the potential health hazards 
of skin contact with methyl cellosolve and 
the rationale behind the SK assignment. 
2 Systemic Toxicity from Skin 
Exposure (SK: SYS)
A number of studies investigated the 
percutaneous absorption of methyl cello-
solve. Kezic et al. [1997] exposed an area 
of about 1000 square centimeters (cm2) of 
the forearm and hand of healthy volun-
teers to vapors of methyl cellosolve (4000 
milligrams per cubic meter [mg/m3]) for 
45 minutes. Those investigators also filled 
1 Introduction
1.1 General Substance Information
Chemical: Methyl Cellosolve
CAS No: 109–86–4
Synonyms:
EGME; Ethylene Glycol Mono-
methyl Ether; Glycol Monomethyl 
ether; 2-Methoxyethanol
Molecular weight (MW): 76
Molecular formula: C3H8O2
Structural formula:
Uses:
Methyl cellosolve is used primarily as a 
jet fuel additive and as an organic sol-
vent [Boatman and Knaak 2001].
HO CH3
O
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a gas chamber with an area of 27 cm2 
with liquid methyl cellosolve and placed 
the chamber on the volar forearm of the 
volunteers for 15 minutes. On the basis 
of measurements of the main urinary me-
tabolite, methoxyacetic acid, the investiga-
tors concluded that both vapor and liquid 
methyl cellosolve were readily absorbed 
through the skin, with an average absorp-
tion rate of 2.9 milligrams per square cen-
timeter per hour (mg/cm2/hr) for liquid 
and a penetration rate of 36 centimeter 
per hour (cm/hr) for vapor. Kezic et al. 
[1997] estimated uptake through the skin 
to be 55% of the total uptake of methyl 
cellosolve in a combined inhalation and 
dermal exposure when the whole body 
surface was exposed to the vapor. Dur-
ing the inhalation experiments, airborne 
concentrations of methyl cellosolve vapor 
were estimated at 16 mg/m3. Kezic et al. 
[1997] reported that during contact of 
both hands and forearms (10% of the total 
body surface area) with liquid methyl cel-
losolve for 60 minutes, dermal absorption 
was more than 100 times the inhalation 
absorption during an 8-hour exposure to 
16 mg/m3 methyl cellosolve vapor. 
Sabourin et al. [1992] noted a linear rela-
tionship between the absorption and the 
applied dermal dose; dermal absorption 
ranged from 19.4% to 26.9% following 
nonoccluded application of 34.2 to 304 
milligrams per kilogram body weight (mg/
kg) on the clipped backs of rats. The po-
tential of methyl cellosolve to pose a skin 
absorption hazard was also evaluated, with 
use of a predictive algorithm for estimat-
ing and evaluating the health hazards of 
dermal exposure to substances [NIOSH 
2009]. The evaluation method compares 
an estimated dose accumulated in the body 
from skin absorption and an estimated dose 
from respiratory absorption associated with 
a reference occupational exposure limit. On 
the basis of this algorithm, a ratio of the 
skin dose to the inhalation dose (SI ratio) of 
588.5 was calculated for methyl cellosolve. 
An SI ratio of ≥0.1 indicates that a chemi-
cal is capable of producing systemic toxicity 
from skin exposure [NIOSH 2009]. Addi-
tional information on the SI ratio and the 
variables used in its calculation are included 
in the appendix. 
No dermal lethal dose (LDLo) for humans 
has been identified. However, the reported 
values for dermal LD50 (the dose resulting 
in 50% mortality in the exposed popula-
tion) in rabbits range from 0.891milliliter 
per kilogram body weight (mL/kg), which 
corresponds to 860 mg/kg [Union Car-
bide Corporation 1984] to 1.34 mL/kg 
(corresponding to 1,290 mg/kg) [Carpen-
ter et al. 1956]. The range of LD50 values 
in rabbits is lower than the critical dermal 
LD50 value of 2000 mg/kg body weight 
that identifies chemical substances with 
the potential for acute dermal toxicity 
[NIOSH 2009]. Therefore, methyl cello-
solve is considered acutely toxic following 
dermal exposure. 
Table 1. Summary of the SK assignment for methyl cellosolve
Skin notation Critical effect Data available
SK: SYS Central nervous system 
(CNS) effects; 
Reproductive toxicity; 
Developmental toxicity;  
Hematologic effects; 
Immunotoxicity
Sufficient human and animal data
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Several case studies were identified that 
reported neurological effects following oc-
cupational exposures to methyl cellosolve. 
Within these reports, the contribution of 
exposure via the inhalation route cannot be 
excluded, but the authors indicate that der-
mal exposure to methyl cellosolve was the 
primary exposure pathway within each case. 
Ohi and Wegman [1978], Donley [1936], 
and Parsons and Parsons [1938] reported 
adverse central nervous system (CNS) ef-
fects (i.e., encephalopathy) and hemato-
toxic effects (i.e., bone marrow depression, 
anemia, and leukopenia) in workers ex-
posed dermally to methyl cellosolve. Im-
munological effects have been reported 
to occur in workers following prolonged 
dermal and inhalation exposure, for 8 to 
35 years [Denkhaus et al. 1986]. Welch 
and Cullen [1988] and Shih et al. [2003] 
reported various hematological effects 
(anemia, granulocytopenia, and low poly-
morphonuclear leukocyte count) among 
workers exposed to methyl cellosolve in a 
cross-sectional study and a follow-up study. 
In a reported case, macrocytic anemia and 
reversible subjective CNS effects occurred 
in a worker with inhalation and dermal ex-
posures to methyl cellosolve during micro-
film manufacturing [Cohen 1984]. 
Epidemiologic studies that concerned the 
reproductive and developmental effects of 
methyl cellosolve in exposed workers were 
identified. Several studies have revealed in-
creased frequency of spontaneous abortions, 
disturbed menstrual cycles, and subfertility 
in female workers [Pastides et al. 1988; Es-
kenazi et al. 1995; Gold et al. 1995; Schen-
ker 1995; Pinney and Lemasters 1996] 
and increased frequency of reduced sperm 
counts and a decrease in testicular size in 
males [Cook et al. 1982; Welch et al. 1988]. 
However, no exposure data are available to 
evaluate the dose response for these effects. 
As a result of extensive, prolonged dermal 
and inhalation exposure to unspecified 
amounts of methyl cellosolve and ethylene 
glycol in a factory, the children of workers 
developed dysmorphic features as well as 
persistent cytogenetic damage, including 
polyploidy, endoreduplication, and mental 
retardation [Saavedra and Tena 1997; El-
Zein et al. 2002]. 
The hematological changes seen in hu-
mans have been observed in animals as well. 
Hobson et al. [1986] reported significant 
changes in hematological parameters (de-
creased red blood cell [RBC] counts and in-
creased mean corpuscular volume [MCV]); 
increased urinary calcium values; statisti-
cally significantly reduced body, testicular, 
and splenic weights; and testicular lesions 
(moderate to severe segmental degeneration 
of the seminiferous tubules) in guinea pigs 
tested at 1000 mg/kg/day (the only dose 
tested). The neat chemical was applied to 
the shaved backs of the animals under gauze 
patches 6 hours per day, 5 days per week, for 
13 weeks. Fairhurst et al. [1989] exposed 
clipped skin of rats to 99% pure methyl cel-
losolve at concentrations of 10 or 1000 mil-
ligrams per kilogram per day (mg/kg/day) 
under occlusive or nonocclusive conditions 
on 5 consecutive days per week for 28 days. 
In comparison with that in control animals, 
body weight gain was reduced in the oc-
cluded animals at applications of 10 mg/
kg/day and above and also in the nonoc-
cluded animals, but only at applications of 
1000 mg/kg/day. The statistical significance 
of the change was not reported. Addition-
ally, methyl cellosolve caused hematological 
effects (a decrease in the number of reticu-
locytes and increases in RBC count, white 
blood cell count, hemoglobin, MCV, and 
packed cell volume) and histopathological 
changes in the testis (described in more de-
tail below) and bone marrow (generalized 
hypocellularity) in occluded animals treated 
at 1000 mg/kg/day. Results in the studies 
of Fairhurst et al. [1989] and Hobson et al. 
4 Skin Notation Profiles | Methyl Cellosolve
M
ethyl Cellosolve
[1986] show a lowest-observed-adverse-
effect level (LOAEL) of 1000 mg/kg/day, 
with some indication of effects at doses as 
low as 10 mg/kg/day.
Dermal studies in animals showed that 
methyl cellosolve is a reproductive and 
developmental toxicant. Methyl cello-
solve topically applied to guinea pigs for 
13 weeks at a dosage of 1000 mg/kg/day 
caused statistically significant reductions 
in testicular weight as well as testicular 
lesions [Hobson et al. 1986]. The same 
dose applied for 28 days also caused his-
topathological changes in the testes of 
rats, described as depletion of pachytene 
spermatocytes, almost complete absence 
of spermatids, and reduction in the ger-
minal epithelium of the tubules [Fairhurst 
et al. 1989]. Feuston et al. [1989] reported 
that repeated dermal exposure to methyl 
cellosolve in rats for 7 consecutive days in-
duced effects on the testes (including de-
clines in epididymal sperm count and tes-
ticular spermatid count and reductions in 
weight of the testes and epididymides), on 
sperm parameters (increases in the num-
ber of sperm with abnormal morphology), 
and on fertility (reductions in fertility) at 
625 mg/kg/day (the lowest dose tested) 
and above following occlusive applica-
tion. With nonocclusive conditions, these 
effects were observed at 1250 mg/kg/day 
(the lowest dose tested) and above. 
The developmental toxicity of dermally 
applied methyl cellosolve has also been 
explored. Feuston et al. [1990] reported a 
LOAEL of 500 mg/kg in rats dosed on 
gestation day 12 for maternal toxicity (for 
decrease in mean body weight gain) and 
for developmental toxicity (for increases 
in external, visceral, and skeletal malfor-
mations). The no-observed-adverse-effect 
level (NOAEL) in this study for both 
maternal and developmental toxicity was 
250 mg/kg/day. Wickramaratne [1986] 
exposed the shaved skin of pregnant rats 
to a solution of methyl cellosolve in saline 
for 6 hours a day on gestation days 6 to 17. 
Application of 10 mL/kg of a 10% solu-
tion of methyl cellosolve in physiological 
saline was fetotoxic, causing a decrease in 
fetal survival and a reduction in litter size, 
whereas application of the same volume of 
a 3% solution did not cause any adverse 
effects. On the basis of this study, the NO-
AEL was 3% (corresponding to approxi-
mately 300 mg/kg/day) and the LOAEL 
was 10% (approximately 1000 mg/kg/day). 
Table 2. Summary of the carcinogenic designations* for methyl cellosolve by 
 numerous governmental and nongovernmental organizations
Organization Carcinogenic designation 
NIOSH [2005] None
NTP [2009] None
USEPA [2009] None
IARC [2009] None
EC [2010] None
ACGIH [2001] None
Abbreviations: ACGIH = American Conference of Governmental Industrial Hygienists; EC = European Commission, Joint Re-
search, Institute for Health and Consumer Protection; IARC = International Agency for Research on Cancer; NIOSH = National 
Institute for Occupational Safety and Health; NTP = National Toxicology Program; USEPA = United States Environmental 
Protection Agency.
*Note: The listed cancer designations were based on data from nondermal (such as oral or inhalation) exposure rather than der-
mal exposure.
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The developmental toxicity studies yielded 
evidence of fetotoxicity but did not show 
teratogenic effects as described in the epi-
demiologic study by Saavedra and Tena 
[1997] and El-Zein et al. [2002]. 
Dermal exposure of rats to methyl cel-
losolve under occlusion for 4 consecutive 
days also induced immunotoxicity, as evi-
denced by a decreased ability to produce 
primary antibodies to the antigen at 300 
mg/kg/day and above, decreased thymus 
weight following exposure to 600 mg/kg/
day and above, and reduced spleen weight 
at 900 mg/kg/day and above [Williams et 
al. 1995]. These results are generally con-
sistent with the findings of Hobson et al. 
[1986] and Fairhurst et al. [1989], who 
reported the ability of methyl cellosolve to 
impact hematological parameters and bone 
marrow, although the array of specific ef-
fects in these studies were not entirely con-
sistent with impaired immune function. 
Overall, these studies of repeated dermal 
dosing provide a LOAEL of 625 mg/kg/
day or more for induced reproductive tox-
icity (testicular toxicity and sperm effects) 
[Feuston et al. 1989], and doses in the 
range of 500 mg/kg/day induced develop-
mental toxicity (including malformations) 
in guinea pigs and/or rats [Feuston et al. 
1990]. The NOAEL for maternal and de-
velopmental effects is in the range of 250 
mg/kg/day. The substance may also be im-
munotoxic at doses as low as 300 mg/kg/
day [Williams et al. 1995]. 
No data were identified regarding the car-
cinogenic potential of methyl cellosolve 
following dermal exposure. Table 2 pro-
vides a summary of carcinogenic desig-
nations from multiple governmental and 
nongovernmental organizations for meth-
yl cellosolve. 
Data from the toxicokinetic studies in 
humans [Sabourin et al. 1992; Kezic et 
al. 1997*], acute dermal toxicity studies 
[Carpenter et al. 1956; Union Carbide 
Corporation 1984], and repeat-dose tox-
icity studies in rats [Hobson et al. 1986; 
Wickramaratne 1986; Fairhurst et al. 
1989; Feuston et al. 1989; Williams et 
al. 1995] demonstrate that methyl cello-
solve is absorbed through the skin and can 
cause systemic effects within the CNS, in 
addition to the reproductive, developmen-
tal, hematological, and immune systems. 
Therefore, on the basis of the data for this 
assessment, methyl cellosolve is assigned 
the SK: SYS notation. 
3 Direct Effect(s) on Skin  
(SK: DIR)
No human or animal data were identified 
that assessed the corrosive potential of 
methyl cellosolve. Additionally, no in vitro 
tests for corrosivity in human or animal 
skin models were found. No information 
on occupational exposure has suggested 
that methyl cellosolve is a skin irritant. 
Jacobs et al. [1989] performed a series of 
tests in volunteers that evaluated the skin 
irritation potential of methyl cellosolve by 
measuring cutaneous blood flow values 
with laser Doppler flowmetry following 
occluded application of patches to intact 
forearm. The patches contained approxi-
mately 18 microliters per square centi-
meter (µL/cm2) of undiluted substance, 
applied for 48 hours, or 10% solution of 
the substance in water, applied for 3 hours. 
Neither diluted nor undiluted methyl cel-
losolve was irritating to human skin in that 
study. In the same study, methyl cellosolve 
was not irritating to rabbit skin, according 
to the Draize score for erythema, follow-
ing application of a patch soaked with 0.5 
*References in bold text indicate studies that served 
as the basis of the SK assignment.
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milliliter (mL) of undiluted substance to 
6 cm2 of rabbit skin under occlusion for 
4 hours. In an earlier study conducted ac-
cording to the European Economic Com-
munities (EEC) method, methyl cello-
solve was not irritating after the substance 
was applied to the shaved skin of rabbits 
for 4 hours, and erythema and edema were 
scored on the Draize scale for up to 72 
hours after removal of the patch [ Jacobs 
et al. 1987]. Bushy Run Research Center 
[1984] observed no irritation when rab-
bits were administered 0.5 mL methyl 
cellosolve for 4 hours under occlusion. 
However, Zissu [1995] found methyl 
cellosolve to be slightly irritating to rab-
bit skin according to the Draize method 
but nonirritating according to the EEC 
method. Dugard et al. [1984] utilized hu-
man abdominal whole skin to evaluate the 
skin damage caused by topical applica-
tions of methyl cellosolve. During the in 
vitro study, the authors applied a “damage 
ratio,” which compared the final tritiated 
water permeability constant to the initial 
permeability constant as an indication of 
irreversible alterations in epidermal diffu-
sion barrier function occurring during the 
experiment. Dugard et al. [1984] reported 
a damage ratio of 3.51 for methyl cello-
solve. For comparison purposes, it should 
be noted that the control damage ratio 
values for distilled water contact alone 
were between 1.0 and 2.0. The structure-
activity relationship model (Deductive 
Estimation of Risk from Existing Knowl-
edge, or DEREK™, for Windows) pre-
dicted methyl cellosolve to be negative for 
skin irritation.
The weight of evidence from the standard 
skin irritation studies indicates that meth-
yl cellosolve is not a primary skin irritant. 
Therefore, on the basis of the data for this 
assessment, methyl cellosolve is not as-
signed the SK: DIR notation.
4 Immune-mediated 
Responses (SK: SEN)
There is limited information available to 
evaluate the sensitization potential of 
methyl cellosolve. No specific informa-
tion on skin sensitization due to methyl 
cellosolve is available from occupational 
exposure experience, in spite of extensive 
reports of exposure. Zissu [1995] investi-
gated the potential of methyl cellosolve to 
be a skin sensitizer in the guinea pig maxi-
mization test and found the substance to 
be nonsensitizing. DEREK™ predicted 
ME to be negative for skin sensitization. 
Therefore, on the basis of the data for this 
Table 3. Summary of the previously issued skin hazard  
designations for methyl cellosolve 
Organization Skin hazard designation 
NIOSH [2005] [skin]: Potential for dermal absorption
OSHA [2009] [skin]: Potential for dermal absorption
ACGIH [2001] [skin]: Based on the ready absorption through the skin in 
amounts sufficient to elicit systemic toxicity
EC [2010] R21: Harmful if in contact with skin
R43: May cause sensitization by skin contact
Abbreviations: ACGIH = American Conference of Governmental Industrial Hygienists; EC = European Commission, Joint 
Research, Institute for Health and Consumer Protection; NIOSH = National Institute for Occupational Safety and Health; 
OSHA = Occupational Safety and Health Administration.
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assessment, methyl cellosolve is not as-
signed the SK: SEN notation. 
5 Summary
Sufficient data were identified from toxi-
cokinetic studies in humans [Dugard et 
al. 1984; Sabourin et al. 1992; Kezic et 
al. 1997], acute dermal toxicity studies 
[Carpenter et al. 1956; Union Carbide 
Corporation 1984], and repeat-dose tox-
icity studies in rats [Hobson et al. 1986; 
Wickramaratne 1986; Fairhurst et al. 
1989; Feuston et al. 1989; Williams et 
al. 1995] to demonstrate that methyl cel-
losolve is absorbed through the skin, is 
systemically available, can cause systemic 
effects within the CNS, in addition to 
the reproductive, developmental, hema-
tological, and immune systems. Standard 
skin irritation studies in rabbits show that 
methyl cellosolve is not a primary skin 
irritant. A guinea pig maximization test 
demonstrated that methyl cellosolve was 
not a skin sensitizer. Therefore, for this as-
sessment, a SK: SYS notation is assigned 
to methyl cellosolve. 
Table 3 summarizes the skin hazard des-
ignations for methyl cellosolve previously 
issued by NIOSH and other organiza-
tions. The equivalent dermal designations 
for methyl cellosolve, according to the 
Global Harmonization System (GHS) of 
Classification and Labelling of Chemi-
cals, are Acute Toxicity Category 4 (Haz-
ard statement: Harmful in contact with 
the skin) and Skin Irritation Category 2 
(Hazard statement: Causes skin irritation) 
[European Parliament 2008]. Methyl cel-
losolve has been identified as a Category 
1B Reproductive toxicant (Hazard state-
ments: May damage fertility; May dam-
age the unborn child) [European Parlia-
ment 2008].
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quirement and can operate entirely on the 
basis of the physicochemical properties 
of a substance and the relevant exposure 
parameters. Thus, the algorithm is inde-
pendent of the need for biologic data. Al-
ternatively, it can function with both the 
physicochemical properties and the ex-
perimentally determined permeation co-
efficient when such data are available and 
appropriate for use.
The first step in the evaluation is to deter-
mine the Kp for the substance to describe 
the transdermal penetration rate of the 
substance [NIOSH 2009]. The Kp, which 
represents the overall diffusion of the sub-
stance through the stratum corneum and 
into the blood capillaries of the dermis, is 
estimated from the compound’s molecular 
weight (MW) and base-10 logarithm of 
its octanol–water partition coefficient (log 
KOW). In this example, Kp is determined 
for a substance with use of Equation 1. A 
self-consistent set of units must be used, 
such as cm/hr, outlined in Table A1. Oth-
er model-based estimates of Kp may also 
be used [NIOSH 2009].
Equation 1: Calculation of Skin Permeation 
Coefficient (Kp)
where Kpsc is the permeation coefficient in 
the lipid fraction of the stratum corneum, 
Kpol is the coefficient in the protein frac-
tion of the stratum corneum, and Kaq is 
the coefficient in the watery epidermal 
This appendix presents an overview of the 
SI ratio and a summary of the calculation of 
the SI ratio for methyl cellosolve. Although 
the SI ratio is considered in the determina-
tion of a substance’s hazard potential fol-
lowing skin contact, it is intended only to 
serve as supportive data during the assign-
ment of the NIOSH SK. An in-depth dis-
cussion on the rationale and calculation of 
the SI ratio can be found in Appendix B of 
the Current Intelligence Bulletin (CIB) 61: 
A Strategy for Assigning New NIOSH Skin 
Notations [NIOSH 2009]. 
Overview 
The SI ratio is a predictive algorithm for 
estimating and evaluating the health haz-
ards of skin exposure to substances. The al-
gorithm is designed to evaluate the poten-
tial for a substance to penetrate the skin 
and induce systemic toxicity [NIOSH 
2009]. The goals for incorporating this 
algorithm into the proposed strategy for 
assigning the SYS notation are as follows:
1. Provide an alternative method to 
evaluate substances for which no 
clinical reports or animal toxicity 
studies exist or for which empirical 
data are insufficient to determine 
systemic effects.
2. Use the algorithm evaluation re-
sults to determine whether a sub-
stance poses a skin absorption haz-
ard and should be labeled with the 
SYS notation.
The algorithm evaluation includes three 
steps: (1) determining a skin permeation 
coefficient (Kp) for the substance of in-
terest, (2) estimating substance uptake by 
the skin and respiratory absorption routes, 
and (3) evaluating whether the substance 
poses a skin exposure hazard.
Appendix: Calculation of the SI Ratio for Methyl Cellosolve
12 Skin Notation Profiles | Methyl Cellosolve
M
ethyl Cellosolve
layer. These components are individually 
estimated by
log Kpsc = −1.326 + 0.6097 × log KOW 
− 0.1786 × MW0.5
Kpol = 0.0001519 × MW−0.5
Kaq = 2.5 × MW−0.5
The second step is to calculate the biologic 
mass uptake of the substance from skin 
absorption (skin dose) and inhalation (in-
halation dose) during the same period of 
exposure. The skin dose is calculated as a 
mathematical product of the Kp, the water 
solubility (SW) of the substance, the ex-
posed skin surface area, and the duration of 
exposure. Its units are milligrams (mg). As-
sume that the skin exposure continues for 8 
hours to unprotected skin on the palms of 
both hands (a surface area of 360 cm2). 
Equation 2: Determination of Skin Dose 
Skin dose = Kp × SW × Exposed skin 
surface area × Exposure time
= Kp(cm/hr) × SW (mg/cm3) × 
360 cm2 × 8 hours
The inhalation dose (in mg) is derived 
on the basis of the occupational exposure 
limit (OEL) of the substance—if the OEL 
is developed to prevent the occurrence of 
Table A1. Summary of data used to calculate the SI ratio for methyl cellosolve 
Variables used in calculation Units Value
Skin permeation coefficient
Permeation coefficient of stratum corneum lipid path(Kpsc) cm/hr 0.00044
Permeation coefficient of the protein fraction of the 
stratum corneum (Kpol)
cm/hr 1.74127 × 10-5
Permeation coefficient of the watery epidermal layer (Kaq) cm/hr 0.28658
Molecular weight (MW)* amu 76
Base-10 logarithm of its octanol–water partition 
coefficient (log KOW)*
None -0.77
Calculated skin permeation coefficient (Kp) cm/hr 0.00046
Skin dose
Water solubility (SW)* mg/cm3 1000
Calculated skin permeation coefficient (Kp) cm/hr 0.00046
Estimated skin surface area (palms of hand) cm2 360
Exposure time hr 8
Calculated skin dose mg 1324.17
Inhalation dose
Occupational exposure limit (OEL)† mg/m3 0.3
Inhalation volume m3 10
Retention factor (RF) None 0.75
Inhalation dose mg 2.25
Skin dose–to–inhalation dose (SI) ratio None 588.52
*Variables identified from SRC [2009].
†The OEL used in calculation of the SI ratio was the NIOSH-recommended exposure limit (REL) [NIOSH 2005].
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systemic effects rather than sensory/irritant 
effects or direct effects on the respiratory 
tract. Assume a continuous exposure of 
8 hours, an inhalation volume of 10 cubic 
meters (m3) inhaled air in 8 hours, and a 
factor of 75% for retention of the airborne 
substance in the lungs during respiration 
(retention factor, or RF).
Equation 3: Determination of Inhalation Dose
Inhalation dose = OEL × Inhalation 
volume × RF
= OEL (mg/m3) × 10 m3 
× 0.75
The final step is to compare the calculated 
skin and inhalation doses and to present 
the result as a ratio of skin dose to inhala-
tion dose (the SI ratio). This ratio quan-
titatively indicates (1) the significance 
of dermal absorption as a route of occu-
pational exposure to the substance and 
(2)  the contribution of dermal uptake to 
systemic toxicity. If a substance has an SI 
ratio greater than or equal to 0.1, it is con-
sidered a skin absorption hazard.
Calculation 
Table A1 summarizes the data applied in 
the previously described equations to deter-
mine the SI ratio for methyl cellosolve. The 
calculated SI ratio was 588.52. On the basis 
of these results, methyl cellosolve is predict-
ed to represent a skin absorption hazard.
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